Fresenius Kabi and Bayer Schering Pharma sign HESylation agreement

German firms Fresenius Kabi and Bayer Schering Pharma have signed a licensing agreement regarding limited use of Fresenius" HESylation technology. The technology is based on hydroxyethyl starch (HES) and prolongs the active half-life of proteins.

German firms Fresenius Kabi and Bayer Schering Pharma have signed a licensing agreement regarding limited use of Fresenius" HESylation technology. The technology is based on hydroxyethyl starch (HES) and prolongs the active half-life of proteins.

Fresenius Kabi will provide the appropriate HES derivative to Bayer Schering Pharma and Bayer Schering will oversee the development and commercialisation. Fresenius Kabi will receive milestone payments and royalties on sales.

HESylation technology allows a targeted modification of drugs and their characteristics by a site-specific coupling to HES molecules. This can modify key pharmacological parameters such as absorption, metabolisation, half-life, water solubility and safety.

Companies